PhRMA Will Keep Focus On Innovation, Access To Protect The Castle, New Chairman Suggests
Incoming PhRMA Chairman Robert Hugin, CEO of Celgene, outlines the organization’s advocacy priorities for protecting innovation and patient access to medicines, emphasizing “we have to have a good defense; we have to play this part of the game.”
You may also be interested in...
The estimated reduction, included in the White House Office of Management and Budget’s report to Congress, is equal the cost of 900 to 1,200 agency employees, an agency advocate said.
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.